Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

roducts, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...e-FirstCall/ -- BlueFire Ethanol Fuels, Inc. (OTC ...ng the world,s transportation fuel paradigm throug...ic wastes, has been ranked number 19 on the Biofu...ioenergy;" the company,s second consecutive year i...Ethanol among the top 20 bioenergy companies for t...
(Date:12/3/2009).../ -- Nikon Corporation, an innovator of advanced o...gned a licensing agreement with Harvard University...ptical Reconstruction Microscopy (STORM) technolog...nufacture STORM enabled microscopy systems and mar...ration President, Mr. Michio Kariya, and Nikon Ins...
(Date:12/3/2009)...FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: ...elopment of compounds for the treatment of cardiov...t it has completed the last patient visit in its P...The FDG-PET trial enrolled 52 patients and was car...ing Massachusetts General Hospital, Mount Sinai Sc...
(Date:12/3/2009)...ire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ...ase its financial results for the second quarter o...m. EST and will host a conference call and webcast...ame day. ,, Peregrine,s senior management will ...nded October 31, 2009 and will review recent opera...
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...y unveils landmark program to help clients avoid c...n collecting outcomes data, LINCOLN, R.I., July 1... questioning the integrity of outcomes data in cli...rsy has been in the news. The,truth is, no matter ...d,for, mistakes are easy to make and difficult to ...
...TON, N.J., July 15 Pharmasset, Inc.,(Nasdaq: VRU...itive,agreements dated July 14, 2008 with a select...0 shares of its common stock in a "registered,dire...e the shares at a,purchase price of $17.85 per sha...5.9 million to Pharmasset, before deducting placem...
...A, July 15 CryoLife, Inc. (NYSE: CRY ),a biomate...y, announced,today that second quarter 2008 financ... 2008. The Company will hold a teleconference call... 31, 2008, to discuss the,results, followed by a q...erson, president and CEO of CryoLife, Inc., To li...
Other Biology Technology:QualityMetric Announces QM Certified Scoring Program 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 3CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:12/4/2009)...matical model of heart cells, University of Iowa i...al enzyme, calmodulin kinase II (CaM kinase), disr... The study, which also involved Columbia Universit...S Computational Biology . , "Recently, research...nase II as a critical regulator of the heart,s res...
(Date:12/3/2009)... N.J., Dec. 3 BIO-key In...ader in wireless public safety and finger-based bi... majority of its shareholders at a Special Shareho...ompany,s Law Enforcement Division to Interact911 M... cast in favor and 1.2% were opposed. ,, (Logo:...
(Date:12/3/2009)...learn new information and adapt to changes in our ...emories, appears to lie in the minute junctions wh...udy by NYU Langone Medicine Center researchers. Th...al Nature . , The scientists, led by Wen-Biao ...uroscience at NYU School of Medicine, discovered t...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Lifelong memories linked to stable nerve connections 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 1AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 3AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 4NIA Says Health Care Will Cause U S Dollar Collapse 50998 1NIA Says Health Care Will Cause U S Dollar Collapse 50998 2NIA Says Health Care Will Cause U S Dollar Collapse 50998 3Spa Chefs Prepare You for a Healthy Summer 50996 1Spa Chefs Prepare You for a Healthy Summer 50996 2
...niversity Medical Center scientists have developed...ents with early-stage lung cancer will need chemot...xic regimen of drugs. , The test has the potenti...nding chemotherapy for patients who are currently ...Duke,s Institute for Genome Sciences & Policy....
...wing gentle puffs of air onto a mouse,s whiskers a...iscovering that a long-overlooked signaling system... , The work is the latest in a growing body of evi...ytes aren,t simply support cells but are stars of ...he University of Rochester Medical Center who did ...
...ein long thought to provide only mechanical suppor...ling apart turns out to have much wider utility. I...d to also influence wound healing and maintain the... to Johns Hopkins researchers. , The wound-healing...eds light on how the body repairs wounds and may h...
Other Biology News:First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Flick of whiskers helps tease out brain's 'shadow' signaling system 2Flick of whiskers helps tease out brain's 'shadow' signaling system 3Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 2Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 3
Nick Translation System from Invitrogen
...ble, easy-to-use and makes identifying your sample...asy to use Labels withstand extreme lab conditio...te stamp Laboratory symbols Affordable-every t...re efficient Banner mode for general labeling ...
cAMP[125I] Direct SPA Screening Biotrak Assay from GE Healthcare, formerly Amersham Biosciences
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: